MARKET

ARMP

ARMP

Armata Pharmctcl
AMEX
2.010
-0.270
-11.84%
Closed 13:00 11/25 EST
OPEN
1.850
PREV CLOSE
2.280
HIGH
2.100
LOW
1.850
VOLUME
14.19K
TURNOVER
8.51K
52 WEEK HIGH
6.46
52 WEEK LOW
1.850
MARKET CAP
72.65M
P/E (TTM)
-1.9566
1D
5D
1M
3M
1Y
5Y
Why Richardson Electronics Shares Surged Over 8%; Here Are 55 Biggest Movers From Friday
Benzinga · 11h ago
Here's Why Armata Pharmaceuticals, Inc. (ARMP) Looks Ripe for Bottom Fishing
Armata Pharmaceuticals, Inc. (ARMP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the ne...
Zacks · 11/15 14:55
Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday
Benzinga · 11/15 10:19
Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
Benzinga · 11/14 18:05
Armata Pharmaceuticals GAAP EPS of -$0.24 beats by $0.04, revenue of $1.34M misses by $0.32M
Seekingalpha · 11/09 22:21
Armata Pharmaceuticals Q3 EPS $(0.24) Down From $(0.21) YoY, Sales $1.34M Up From $1.25M YoY
Benzinga · 11/09 22:11
Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday
Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.
Benzinga · 09/19 05:53
US Stocks Turn Lower; Nasdaq Drops Over 100 Points
U.S. stocks turned lower midway through trading, with the Nasdaq Composite dropping more than 100 points on Thursday.
Benzinga · 09/15 16:04
More
About ARMP
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using bacteriophage-based technology. It has developed care therapies, including the multidrug-resistant or superbug strains of bacteria. The Company is a developer of phage therapeutics, which are positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections. It is developing and advancing its lead clinical phage candidate for Pseudomonas aeruginosa. The Company is also developing a phage product candidate for Staphylococcus aureus for the treatment of staphylococcus aureus bacteremia. It has phage development to target other indications, including non-cystic fibrosis bronchiectasis (NCFB), prosthetic joint infections (PJI) and hospitalized pneumonia. Its product candidates are AP-PA02, AP-PA03 and AP-SA02.

Webull offers kinds of Armata Pharmaceuticals Inc stock information, including AMEX:ARMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARMP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARMP stock methods without spending real money on the virtual paper trading platform.